In addition to anti-cancer activity, pre-clinical and clinical studies of CB1R inverse agonists have shown that drugs with this mechanism of action reduce appetite, body weight, insulin resistance, and hepatic steatosis, while CB2R inverse agonists act as potent and efficacious anti-inflammatory agents in a variety of disease states (Tam et al., 2012; Presley et al., 2015). Here, CNR1 is linked to Insulin resistance.